Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD (SEQUENTIAL)

This study has been completed.
Sponsor:
Information provided by:
Janssen-Cilag International NV
ClinicalTrials.gov Identifier:
NCT00908232
First received: May 21, 2009
Last updated: May 4, 2012
Last verified: May 2012
  Purpose

The purpose of this study is to test the effectiveness and safety of adding cyclophosphamide or lenalidomide to the VD combination in the treatment of patients with multiple myeloma that have achieved a stable response after 4 initial cycles of treatment with VD. Multiple myeloma is the second most common cancer of the blood. Bortezomib disrupts the life cycle of the cell, affecting numerous biologic pathways, including those related to growth and survival of cancer cells.


Condition Intervention Phase
Multiple Myeloma
Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Dexamethasone
Drug: Lenalidomide
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD

Resource links provided by NLM:


Further study details as provided by Janssen-Cilag International NV:

Primary Outcome Measures:
  • Assessment of the Efficacy of Adding Either Cyclophosphamide or Lenalidomide to the Combination of Velcade and Dexamethasone on the Overall Response Rate. [ Time Frame: Response to therapy Day 1 of Cycle 1 (baseline), at Day 1 of all subsequent cycles, at the End of Treatment visit and at every Follow-up Visit (monthly) until there is evidence of Progressive Disease or relapse or until start of alternative MMY treatment ] [ Designated as safety issue: No ]
    Overall Response Rate as defined by the combination of subjects with Complete Response, Very Good Partial Response and Partial Response according to the International Myeloma Working Group 2006 criteria (IMWG). Response to therapy was followed by measurement of M-protein in serum and urine.


Secondary Outcome Measures:
  • Overall Response Rate for Non-randomized Patients Cycle 5 to 8 [ Time Frame: Prior to treatment at day 1 of each cycle and at the end of treatment (day 21 of cycle 8) ] [ Designated as safety issue: No ]
    Overall response rate as defined by the combination of subjects with complete response, very good partial response and partial response according to the International Myeloma Working Group 2006 criteria (IMWG). Response to therapy was followed by measurement of M-protein in serum and urine.

  • Assessment of the Safety Profile and Additional Efficacy Parameters Including the Time to Response, Duration of Response, Progression Free Survival, the Time to Progression, the One Year Survival and the Overall Survival of the Patients [ Time Frame: Day 1 of each cycle, 30 days after last dose of study drug, monthly until relapse or Progressive Disease / SAEs: from informed consent signature until 30 days after last dose of study drug (when occurring after 30 days, reported if related to study drug) ] [ Designated as safety issue: Yes ]

Enrollment: 163
Study Start Date: April 2008
Study Completion Date: August 2011
Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Stable Disease: VD
Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
Drug: Bortezomib
1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
Drug: Dexamethasone
20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
Experimental: Stable Disease: VDC
Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and cyclophosphamide 500 mg, orally daily, days 1, 8 and 15 for cycle 5 to 8
Drug: Cyclophosphamide
500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
Drug: Bortezomib
1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
Drug: Dexamethasone
20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
Experimental: Stable Disease: VDL
Stable disease after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8 and 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8 and lenalidomide 10 mg orally daily from day 1 to day 14 for cycle 5 to 8
Drug: Bortezomib
1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
Drug: Dexamethasone
20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
Drug: Lenalidomide
10 mg orally daily, days 1-14 for cycles 5 to 8
Experimental: Complete to Partial Response: VD
Complete, very good partial or partial response after 4 cycles bortezomib + dexamethasone: bortezomib 1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 in combination with dexamethasone 20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycle 1 to 8
Drug: Bortezomib
1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
Drug: Dexamethasone
20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8

Detailed Description:

It has been shown that quality of response corresponds with clinical benefit. Stable disease is not regarded as a satisfactory result of therapy for relapsed and refractory multiple myeloma. However, there is no consensus if, when and how treatment should be continued or changed in the case of stable disease.

There are different strategies of achieving an optimal quality of response in relapsed and refractory multiple myeloma. One is to treat for a longer duration with one regimen. The alternative path can be a sequential approach adding another agent to the initial regimen depending on the outcome of therapy after a defined treatment period. These two principles will be evaluated in the present study.

Both Cyclophosphamide and Lenalidomide have proven to be efficacious in multiple myeloma and combinations of both agents with bortezomib and Dexamethasone have been shown to be active and tolerable.

In this study patients with relapsed/progressive or refractory multiple myeloma will start treatment with bortezomiib and Dexamethasone. Response will be evaluated after four cycles. Patients with complete, very good partial response or partial response will continue treatment as initiated. Patients with stable disease will either continue treatment with the bortezomib/Dexamethasone combination for another four cycles or will receive Cyclophosphamide or Lenalidomide as an additional third agent for another four cycles.

Patients with multiple myeloma that are refractory to or have relapsed/progressed after primary treatment for multiple myeloma will be enrolled in the study. All patients will receive a combination of bortezomib plus dexamethasone for a total of four cycles. Based on the response to this treatment, further study treatment is customized. Patients with a complete, a very good partial or a partial response will continue to receive bortezomib and Dexamethasone for a maximum additional four cycles, to an overall maximum of eight cycles. Patients achieving stable disease, as defined by International Myeloma Working Group 2006 (IMWG 2006) response criteria, will undergo a central randomisation to continue treatment with VD or VD plus cyclophosphamide or VD plus lenalidomide. Patients with progressive disease will go off study treatment. After randomisation, patients will receive therapy for up to four additional treatment cycles, to an overall maximum of eight cycles. Each cycle will consist of three weeks treatment. There will be a long-term follow-up period with monthly visits until relapse or progressive disease. Thereafter follow-up for survival will be continued by at least a phone call every other month. This will be performed for all patients until the last patient was treated and followed up for 1 year.

Safety will be assessed by the monitoring of adverse events, physical examination (including neurological/peripheral neurological examinations), pulmonary examinations, vital signs measurements, and clinical laboratory tests.

Patients will be treated in a 3-week cycle, up to a maximum of 8 cycles bortezomib 1.3 mg/m2 will be administered on day 1, 4, 8 and 11 as i.v. bolus infusion.

Dexamethasone 20 mg po will be administered on days 1, 2, 4, 5, 8, 9, 11, 12. Dexamethasone will be administered as 2 tables of 8 mg plus 1 tablet of 4 mg Cyclophosphamide 500 mg po will be administered as 10 tablets of 50 mg on day 1, 8, 15 Lenalidomide will be administered as once daily 10 mg tablet from day 1 to 14

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient has relapsed/progressed or is refractory for multiple myeloma following 1 previous line of therapy
  • Measurable secretory multiple myeloma: measurable disease for secretory multiple myeloma is defined by at least one of the following measurements: serum monoclonal protein greater than or equal to 1 g/dl (> 10 gm/l) [10g/l], urine M-protein of ≥200 mg/24 hours
  • Patient has a Karnofsky performance status of ≥ 60
  • Patient has a life expectancy estimated at screening of at least 6 months
  • Patient fulfills defined pretreatment laboratory requirements at and within 14 days before baseline

Exclusion Criteria:

  • Patient received more than 1 previous line of therapy for multiple myeloma
  • Patient has known allergy or hypersensitivity to bortezomib, Dexamethasone and/or Cyclophosphamide and/or Lenalidomide or any of the constituent compounds such as boron, mannitol, or lactose
  • Patient has oligosecretory or non-secretory multiple myeloma
  • Patient received nitrosoureas or any other chemotherapy (including thalidomide), clarithromycin, interferon within 6 weeks before enrolment. Note: subjects can have received thalidomide or interferon as maintenance therapy, according to local standard of care
  • Patient received corticosteroids (> 10 mg/day prednisone or equivalent) within 3 weeks before enrolment. Note: subjects can have received steroids (dexamethasone or equivalent) as maintenance therapy according to local standard of care. In addition, subjects can have received a cumulative dose of up to 160 mg of dexamethasone or equivalent as emergency therapy within 3 weeks prior to study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00908232

  Show 44 Study Locations
Sponsors and Collaborators
Janssen-Cilag International NV
Investigators
Study Director: Janssen-Cilag International NV Clinical Trial Janssen-Cilag International NV
  More Information

No publications provided

Responsible Party: EMEA Medical Affairs Director Oncology, Janssen-Cilag International NV
ClinicalTrials.gov Identifier: NCT00908232     History of Changes
Other Study ID Numbers: CR013165, 26866138MMY2045, 2007-001462-33
Study First Received: May 21, 2009
Results First Received: May 4, 2012
Last Updated: May 4, 2012
Health Authority: Belgium: Ministry of Social Affairs, Public Health and the Environment

Keywords provided by Janssen-Cilag International NV:
multiple myeloma
bortezomib
hematology
bone marrow cancer
immunoglobulin
refractory
progression
dexamethasone
lenalidomide
cyclophosphamide

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Cyclophosphamide
Thalidomide
Bortezomib
Lenalidomide
Dexamethasone
Dexamethasone acetate
Dexamethasone 21-phosphate
BB 1101
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents, Alkylating
Alkylating Agents

ClinicalTrials.gov processed this record on August 28, 2014